Directori de persones
Antonia Salud Salvia

Antonia Salud Salvia

Grau: Doctor/a


masalud.lleida.ics(ELIMINAR)@gencat.cat

Grups

Publicacions

  • Camps Herrero, C; Batista, N; Diaz Fernandez, N; Escobar Alvarez, Y; Gonzalo Gomez, A; Isla Casado, D; Salud, A; Terrasa Pons, J; Guillem Porta, V

    Breakthrough cancer pain: review and calls to action to improve its management

    CLINICAL & TRANSLATIONAL ONCOLOGY 22 1216-1226. .

    [doi:10.1007/s12094-019-02268-8]

  • Porcel, JM; Torres, M; Pardina, M; Civit, C; Salud, A; Bielsa, S

    Predictors of Indwelling Pleural Catheter Removal and Infection A Single-center Experience With 336 Procedures

    JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY 27 86-94. .

    [doi:10.1097/LBR.0000000000000632]

  • Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martínez E; Jorge, M; Arrazubi, V; Méndez JC; García-Alfonso P; Reboredo, M; Barriuso, J; Mu?oz-Unceta, N; Jimeno, R; López C

    Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial (vol 83, pg 1175, 2019)

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 84 1365-1365. .

    [doi:10.1007/s00280-019-03964-6]

  • García-Albéniz X; Alonso, V; Escudero, P; Méndez M; Gallego, J; Rodríguez JR; Salud, A; Fernández-Plana J; Manzano, H; Zanui, M; Falc?, E; Feliu, J; Gil, M; Fernández-Martos C; Bohn, U; Alonso, C; Calderero, V; Rojo, F; Cuatrecasas, M; Maurel, J

    Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)

    Oncologist 24 1115-1122. .

    [doi:10.1634/theoncologist.2018-0728]

  • Fernandez-Martos, C; Pericay, C; Losa, F; Garcia-Carbonero, R; Layos, L; Rodriguez-Salas, N; Martin-Richard, M; Alonso-Orduna, V; Vera, R; Gallego, J; Capdevila, J; Salud, A; Nogue, M; Maurel, J; Guash, I; Montagut, C; Lopez, C; Macias, I; Jain, RK; Garcia-Albeniz, X

    Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial

    JAMA Oncology 5 1566-1573. .

    [doi:10.1001/jamaoncol.2019.2294]

  • Porcel, JM; Esquerda, A; Bielsa, S; Novell, A; Sorolla, MA; Gatius, S; Zamora, C; Vidal, S; Salud, A

    Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions

    RESPIROLOGY 24 799-804. .

    [doi:10.1111/resp.13539]

  • Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; García Alfonso P; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E

    First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    Bmc Cancer 19 533-533. .

    [doi:10.1186/s12885-019-5753-7]

  • Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Muñoz-Unceta N; Jimeno, R; Lopez, C

    Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 83 1175-1181. .

    [doi:10.1007/s00280-019-03820-7]

  • Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E

    Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

    ANNALS OF ONCOLOGY 30 796-803. .

    [doi:10.1093/annonc/mdz082]

  • MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VELASCO SANCHEZ, ANA; MARTINEZ ORTIN, DAVID; SALLA FORTUNY, JOEL; TEJERO NARBONA, RUBEN; SERRATE LOPEZ, ANNA ALBA; VILARDELL VILLELLAS, FELIPE; SALUD SALVIA, ANTONIA

    Clinical and Biological Factors Associated with ISH Amplification in HER2 2+ by IHC in Breast Cancer Patients

    Biomedical Journal of Scientific & Technical Research -. .

    [doi:10.26717/BJSTR.2019.16.002860]

  • Diaz-Serrano, A; Angulo, B; Dominguez, C; Pazo-Cid, R; Salud, A; Jimenez-Fonseca, P; Leon, A; Galan, MC; Alsina, M; Rivera, F; Plaza, JC; Paz-Ares, L; Lopez-Rios, F; Gomez-Martin, C

    Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

    Oncologist 23 1092-1102. .

    [doi:10.1634/theoncologist.2017-0379]

  • Alonso, V; Escudero, P; Fernandez-Martos, C; Salud, A; Mendez, M; Gallego, J; Rodriguez, JR; Martin-Richard, M; Fernandez-Plana, J; Manzano, H; Mendez, JC; Zanui, M; Falco, E; Gil-Raga, M; Rojo, F; Cuatrecasas, M; Feliu, J; Garcia-Albeniz, X; Maurel, J

    Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

    NEOPLASIA 20 678-686. .

    [doi:10.1016/j.neo.2018.05.004]

Projectes

  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante